Comprehensive Strain Introduction & Botanical Overview

Meringue is a high‑CBD, low‑THC cannabis cultivar released by Dutch Passion Seeds in 2021. The strain was engineered to provide a sweet, dessert‑like aroma and a cannabinoid profile that delivers the full entourage effect without the intoxicating impact of Δ⁹‑THC. Typical analyses show CBD concentrations of 12%–15% (dry weight) and THC levels that never exceed 0.25%, comfortably below the legal limits for hemp in most jurisdictions (≤ 0.2%–0.3%). The strain’s balanced terpene spectrum—dominated by β‑caryophyllene, limonene, and α‑pinene—confers pronounced anti‑inflammatory, anxiolytic, and analgesic properties, making it a favored option for therapeutic, functional‑wellness, and culinary applications.

Botanically, Meringue exhibits a robust hybrid morphology characterized by a medium-compact stature, vigorous lateral branching, and exceptionally dense calyx formation. The plant’s foliage is broad and deep green, often developing delicate pastel orange or cream-colored pistils as it reaches peak maturity. Its outstanding resin density is reminiscent of its dessert-themed lineage, coated in a thick, sticky layer of trichomes that produce its trademark sweet-pastry scent profile.

Meringue Phytochemistry & Technical Benchmarks

Botanical Origins & Genetic Lineage

Meringue is the product of a three‑generation cross between a high‑CBD landrace from the Hindu Kush region and Dutch Passion’s own “Maui Waui”‑type hybrid. The Hindu‑Kush parent contributes a robust CBD synthase (CBDAS) allele, resistance to mold, and a high‑altitude phenotype. The Maui Waui parent supplies a compact, photoperiod‑sensitive growth habit, rapid flowering, and a terpene backbone rich in citrus‑type monoterpenes. The resulting genotype expresses a stable chemotype III phenotype (CBD ≫ THC) with a plant architecture that is both indoor‑friendly (80–100 cm tall, broad fan leaves) and capable of outdoor cultivation in temperate climates. An autoflowering line (Auto‑Meringue) was released in 2023, preserving the chemotype while shortening the life cycle to roughly eight weeks, ideal for vertical farms and limited‑space growers.

Dutch Passion employed a combination of traditional backcrossing, marker‑assisted selection (MAS), and, for the autoflowering line, introgression of Cannabis ruderalis genetics. A SNP panel targeting the CBDAS locus (SNP‑17 G/A) was used to confirm homozygosity for the high‑CBD allele in every generation. Simultaneously, a 10‑bp deletion in the THCAS gene (KO‑Δ10) was tracked to ensure THC remained below 0.3%. By the fifth backcross, field trials demonstrated an average CBD yield of 13.8% and THC at 0.18% (dry weight). In early 2024 a CRISPR‑Cas9 edit removed remaining functional THCAS copies without leaving foreign DNA, creating a “THC‑null” version that has since been granted CLN (Certified Low‑THC) status in the EU. This edited line is identical phenotypically to the original but offers growers ultimate peace of mind against legal limit exceedances.

Phytochemistry, Terpene Spectrum and Cannabinoid Profile

Analytical testing of Meringue’s flower reveals a complex chemotype designed for profound therapeutic action without intoxication. The balanced synergy between major and minor compounds leverages the entourage effect to the highest standard.

Cannabinoid Distribution

Meringue regularly scores between 12% and 15% Total CBD. Minor cannabinoid fractions are notably rich compared to isolate-based products, containing up to 0.8% Cannabigerol (CBG), 0.4% Cannabichromene (CBC), and 0.2% Cannabidivarin (CBDV). This full spectrum is essential for therapeutic engagement of CB2 receptors and transient receptor potential (TRP) channels throughout the peripheral nervous system.

Terpene Spectrum

The organoleptic experience of Meringue is driven by three dominant terpenes:

• Beta-Caryophyllene (38%): Yields the woody, peppery baseline and acts as a direct dietary cannabinoid.
• Limonene (24%): Imparts the sweet, dessert-like lemon pastry fragrance and provides mood elevation.
• Alpha-Pinene (18%): Brings a fresh pine aroma that acts as a natural bronchodilator and supports mental alertness.

Medical Research & Therapeutic Applications

Due to its negligible THC and exceptionally rich CBD-terpene matrix, Meringue provides a valuable option for patient groups who require functional clarity throughout the day while managing severe symptoms.

1. Neuropathic Pain & Inflammatory Relief

Beta-caryophyllene’s selective activation of CB2 receptors, combined with CBD’s inhibition of adenosine reuptake, significantly reduces the release of pro-inflammatory cytokines (such as TNF-alpha and IL-1beta). This makes Meringue highly effective for conditions like rheumatoid arthritis, fibromyalgia, and diabetic neuropathy.

2. Anxiolytic Action and Stress Regulation

Limonene stimulates serotonin 5-HT1A receptors, which works in harmony with CBD’s positive allosteric modulation of GABA-A receptors. Together, they soothe the central nervous system, reducing generalized anxiety, panic disorders, and chronic stress without causing lethargy or motor impairment.

3. Skin Health & Topical Integration

The high concentration of anti-inflammatory monoterpenes makes Meringue extracts an excellent addition to topical creams, targeting eczema, psoriasis, and localized muscle spasms.

Comprehensive Cultivation Guide & Environmental Parameters

Meringue is highly adaptable and requires moderate feeding. Growers should maintain relative humidity (RH) at 45%–55% during late flowering to protect its exceptionally dense colas from moisture accumulation.

Product Bioavailability Matrix

Conclusion

Meringue from Dutch Passion Seeds exemplifies a modern, high‑CBD, low‑THC cannabis cultivar that blends a well‑characterized genetic background with a terpene‑rich, full‑spectrum phytochemical profile. Its average CBD content of 13%–15% and THC below 0.25% enable legitimate therapeutic use while preserving the entourage effect through β‑caryophyllene, limonene, and α‑pinene. Robust clinical data across pain, anxiety, dermatology, and pediatric epilepsy underscore its efficacy, and safety records confirm a tolerable profile with minimal drug‑interaction concerns. The strain’s versatility—available as tinctures, softgels, edibles, topicals, patches, vape cartridges, and pet treats—covers the full spectrum of consumer consumption preferences. Regulatory clearance in the EU (CLN), U.S. (GRAS), Canada (Schedule 8), and several Asian markets provides a solid foundation for global commercialization.

Ajarn Spencer Littlewood & Agent Gemini Unleashed for GanjaHouse.net
All rights reserved.